MANUFACTURER REFUND SERVICE
WHAT IS THE MANUFACTURER REFUND SERVICE?
Manufacturer restatements of Average Manufacturer Price (AMP) and/or Medicaid Best Price (BP) can result in a 340B ceiling price recalculation, leading to refunds owed to covered entities (CEs) for past 340B purchases. The 340B Prime Vendor Program (PVP), managed by Apexus, offers a service to handle the resource-intensive, complex task of processing these refunds when necessary.
The 340B PVP Manufacturer Refund Service (MRS) facilitates refunds to CEs by directly refunding affected facilities primarily through the authorized distribution network. This model can be used by manufacturers with varying product portfolios as a solution for large or small refunds alike.
THE 340B PRIME VENDOR FACILITATES THE REFUND PROCESS
340B PVP Manufacturer Refund Service
RECEIVE COMPREHENSIVE REPORTING
A fully auditable final report is provided at project completion.
The 340B Prime Vendor facilitates CE communication, refund processing, and collecting W-9 tax forms. The majority of refund projects are efficiently completed within 90 days with initial communications to CEs within 30 days
INCREASE OPERATIONAL EFFICIENCY
To facilitate budget planning, the Manufacturer Refund Service process is outlined prior to the start of the refund project. The 340B Prime Vendor works with the distributor network and CE relationships as well as its call specialists to process refunds efficiently.
MANUFACTURER REFUND SERVICE OVERVIEW
- Complete data analysis
- Communications template(s)
- Communications with CEs and distributors within 30 days
- CE refunds through distributor credits and checks
- Due diligence calls to send refunds by check or ACH when required
- Collection of CE W-9s
- Weekly status reports
REFUND PROJECT COMPLETION
- Executive summary
- Fully auditable line item detailed reconciliation report
- Preparation and sending of 1099 tax forms as required
340B CMP FINAL RULE
The 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) Regulation (340B CMP Final Rule) became effective January 1, 2019.
Manufacturers are required to charge CEs no more than the 340B ceiling price for covered outpatient drugs under the 340B statute and their pharmaceutical pricing agreement (PPA). Manufacturers are expected to restate and issue refunds for overcharges to CEs.
LEARN MORE ABOUT THE 340B PRIME VENDOR MRS
Contact us for more information or to schedule a presentation.